Standout Papers

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial 2022 2026 2023 2024415
  1. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial (2022)
    W. Timothy Garvey, Rachel L. Batterham et al. Nature Medicine

Immediate Impact

1 from Science/Nature 84 standout
Sub-graph 1 of 20

Citing Papers

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
2025 Standout
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025 Standout
3 intermediate papers

Works of Georgia Rigas being referenced

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
2022 Standout
Gaps to bridge: Misalignment between perception, reality and actions in obesity
2019

Author Peers

Author Last Decade Papers Cites
Georgia Rigas 204 164 353 403 230 18 773
Angela Fitch 210 89 325 374 223 30 805
Altynai Satylganova 146 65 323 431 228 12 717
Michelle Look 176 206 490 401 306 12 823
Arash Pakseresht 215 72 466 645 241 12 883
Todd Hobbs 144 64 97 459 102 27 736
Charles H. Bowden 96 40 468 543 301 8 832
Alison C. Barnes 389 125 87 461 460 25 880
Sarah Steven 418 106 56 410 446 16 883
Charlotte Janus 171 29 240 388 309 20 744
Meera Shah 514 73 107 421 362 37 942

All Works

Loading papers...

Rankless by CCL
2026